Aakaar Medical

Why is Aakaar Medical Technologies Ltd falling/rising?

As of 24-Jun, Aakaar Medical Technologies Ltd's stock price is at 73.30, down 1.0 (-1.35%), but has shown positive trends over the past week and month. Despite a slight year-to-date decline of 0.61%, increased investor participation indicates ongoing interest in the stock.

As of 24-Jun, Aakaar Medical Technologies Ltd's stock price is currently at 73.30, reflecting a decrease of 1.0 (-1.35%). This decline can be attributed to its performance today, where it underperformed the sector by 1.38%. Despite this drop, the stock has shown positive trends over the past week and month, with increases of 3.24% and 5.47%, respectively. Additionally, the stock is trading above its moving averages across various time frames, indicating a generally upward trend in the longer term. However, the year-to-date performance shows a slight decline of 0.61%, which may contribute to investor sentiment affecting the current price. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 19.05% against the 5-day average, suggesting that while the stock is currently falling, there is still interest and activity among investors.

Which are the latest news on Aakaar Medical?

What does Aakaar Medical do?

Aakaar Medical Technologies Ltd is a micro-cap company in the healthcare services industry, with a market cap of INR 94 Cr. It has no reported sales or profits, a P/E ratio of 14.00, and a return on equity of 12.17%.

Overview: <BR>Aakaar Medical Technologies Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>No specific details regarding the incorporation year or status changes are available. Additionally, there are no reported sales or profit figures for any recent quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 94 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: 12.17% <BR>Price-to-Book: 1.73<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Aakaar Medical?

Aakaar Medical's peers include Bilcare, Aspira Pathlab, Star Imaging, Choksi Laborator, Jeevan Scienti., Royal Sense, and Shree Pacetronix. Aakaar Medical has good management risk and growth, with a recent 1-month return of 16.91%, while its six-month return is -14.47%.

Peers: The peers of Aakaar Medical are Bilcare, Aspira Pathlab, Star Imaging, Choksi Laborator, Jeevan Scienti., Royal Sense, and Shree Pacetronix.<BR><BR>Quality Snapshot: Excellent management risk is observed at Star Imaging, Royal Sense, and Shree Pacetronix, while Good management risk is found at Aakaar Medical. Below Average management risk is present at Bilcare, Aspira Pathlab, Choksi Laborator, Jeevan Scienti., and the rest. Growth is Excellent at Royal Sense, Good at Aakaar Medical, Star Imaging, and Shree Pacetronix, while Below Average growth is seen at Bilcare, Aspira Pathlab, and the rest. Average capital structure is found at Aspira Pathlab and Jeevan Scienti., while Below Average capital structure is present at Bilcare, Choksi Laborator, and the rest.<BR><BR>Return Snapshot: Aakaar Medical has a 1-year return of N/A, while the peer with the highest return is Aakaar Medical with a 1-month return of 16.91%, and the peer with the lowest return is Bilcare with a 1-year return of N/A. Additionally, Aakaar Medical's six-month return is negative at -14.47%.

Is Aakaar Medical overvalued or undervalued?

As of November 17, 2025, Aakaar Medical is considered overvalued with a PE ratio of 18.23 and an EV to EBITDA ratio of 12.87, despite being lower than some peers like Sun Pharma and Divi's Lab, while its recent stock performance has underperformed the Sensex with returns of -3.24% over the past week and -11.37% over the past month.

As of 17 November 2025, Aakaar Medical's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 18.23, while the EV to EBITDA ratio is 12.87, and the ROCE is 15.34%. <BR><BR>In comparison to its peers, Aakaar Medical's PE ratio is significantly lower than that of Sun Pharma, which has a PE of 36.69, and Divi's Lab, which is at 69.78. However, it is higher than some peers like Dr. Reddy's Labs, which has a PE of 17.98. The recent performance shows that Aakaar Medical has underperformed the Sensex over the past week and month, with stock returns of -3.24% and -11.37%, respectively, reinforcing the notion of its overvaluation.